Experimental shot targets kidney disease at its source

NCT ID NCT05083364

Completed Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed early-stage trial tested an experimental drug called ARO-C3 in 62 healthy volunteers and patients with two types of kidney disease (C3 glomerulopathy and IgA nephropathy). The drug is designed to calm an overactive part of the immune system that can damage the kidneys. The main goal was to check safety and how the drug moves through the body, with patients receiving three doses over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARO-C3 (an experimental RNA-targeted drug given by injection under the skin)
What this could lead to: If successful, this could lead to a new treatment option for certain kidney diseases caused by an overactive immune system.
What could go wrong: This is an early-phase trial with only 62 participants, so results may not apply to everyone. The drug is still experimental and may not prove safe or effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C3 GLOMERULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

complement 3 glomerulopathy IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C3 GLOMERULOPATHY IGA NEPHROPATHY

Contacts and locations

Locations

Research Site

Auckland, 1010, New Zealand
Research Site 1

Camperdown, New South Wales, 2050, Australia
Research Site 1

Gamcheon, Busan, 49267, South Korea
Research Site 2

Clayton, Victoria, 3168, Australia
Research Site 2

Tbilisi, 0112, Georgia
Research Site 2

Cologne, 50937, Germany
Research Site 2

Haeundae, Busan, 48108, South Korea
Research Site 2

Bangkok, 10400, Thailand
Research Site 3

Concord, New South Wales, 2139, Australia
Research Site 3

Daegu, 42601, South Korea
Research Site 3

Chiang Mai, 50200, Thailand
Research Site 4

Erlangen, 91054, Germany
Research Site 4

Goyang-si, Gyeonggi-do, 10444, South Korea
Research Site 4

Oxford, OX3 7LE, United Kingdom
Research Site 6

Soeul, 03722, South Korea
Research Site 8

Soeul, 05030, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.